Pay in 4 interest-free payments of $5.14 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
FDA-approved tirzepatide is available only as an injection
Research in people using GLP-1s for obesity shows: Nausea, vomiting, diarrhea and constipation are the leading side effects.Nature+1 The risk of these symptoms typically increases with dose, especially during dose escalation.Nature+1 Constipation in particular is reported more often in obesity trials than in diabetes trials.Taylor & Francis Online+1 In everyday language: your digestive system is being asked to slow down and adjust, while your eating patterns and appetite are changingsometimes dramatically and quickly
The trials were funded by Novo Nordisk, the maker of Ozempic and Wegovy
Nutritional Status: Because Tirzepatide reduces appetite significantly, we monitor nutritional deficiencies to ensure your body is getting the vitamins and minerals it needs to thrive
US$ 29.80
US$ 26.41
US$ 26.14
US$ 20.86
